Genelux publishes corporate presentation highlighting Olvi-Vec late-stage ovarian cancer program focused on platinum sensitization

Reuters2026/08/13 20:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Genelux highlighted its pivotal Phase 3 OnPrime/GOG-3076 trial of Olvi-Vec in platinum-resistant or -refractory ovarian cancer.
Topline Phase 3 results expected in 2H 2026; FDA alignment cited as potentially supporting traditional approval without a confirmatory trial.
Phase 2 VIRO-15 data cited: ORR 54% by RECIST; median PFS 11 months; median OS 15.7 months in 27 patients.
Systemic Olvi-Vec programs remain in enrollment for recurrent NSCLC Phase 2, recurrent SCLC Phase 1b/2; dose-finding updates expected in 2026.
Cash as of June 30, 2026 was about $19 million; quarterly operating cash burn averaged about $7 million; cash runway projected to Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Genelux publishes corporate presentation highlighting Olvi-Vec late-stage ovarian cancer program focused on platinum sensitization

You may also like

Crypto prices